These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 30420446)

  • 1. Targeting Purinergic Receptor P2Y2 Prevents the Growth of Pancreatic Ductal Adenocarcinoma by Inhibiting Cancer Cell Glycolysis.
    Hu LP; Zhang XX; Jiang SH; Tao LY; Li Q; Zhu LL; Yang MW; Huo YM; Jiang YS; Tian GA; Cao XY; Zhang YL; Yang Q; Yang XM; Wang YH; Li J; Xiao GG; Sun YW; Zhang ZG
    Clin Cancer Res; 2019 Feb; 25(4):1318-1330. PubMed ID: 30420446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
    McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
    Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AKT/GSK-3beta/VEGF signaling is involved in P2RY2 activation-induced the proliferation and metastasis of gastric cancer.
    Dong CR; Hu DX; Liu SC; Luo HL; Zhang WJ
    Carcinogenesis; 2023 May; 44(1):65-79. PubMed ID: 36469496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased Serotonin Signaling Contributes to the Warburg Effect in Pancreatic Tumor Cells Under Metabolic Stress and Promotes Growth of Pancreatic Tumors in Mice.
    Jiang SH; Li J; Dong FY; Yang JY; Liu DJ; Yang XM; Wang YH; Yang MW; Fu XL; Zhang XX; Li Q; Pang XF; Huo YM; Li J; Zhang JF; Lee HY; Lee SJ; Qin WX; Gu JR; Sun YW; Zhang ZG
    Gastroenterology; 2017 Jul; 153(1):277-291.e19. PubMed ID: 28315323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
    Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB
    Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. cNEK6 induces gemcitabine resistance by promoting glycolysis in pancreatic ductal adenocarcinoma via the SNRPA/PPA2c/mTORC1 axis.
    Li G; She FF; Liao CY; Wang ZW; Wang YT; Wu YD; Huang XX; Xie CK; Lin HY; Zhu SC; Chen YH; Wu ZH; Chen JZ; Chen S; Chen YL
    Cell Death Dis; 2024 Oct; 15(10):742. PubMed ID: 39394197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Constitutive IRAK4 Activation Underlies Poor Prognosis and Chemoresistance in Pancreatic Ductal Adenocarcinoma.
    Zhang D; Li L; Jiang H; Knolhoff BL; Lockhart AC; Wang-Gillam A; DeNardo DG; Ruzinova MB; Lim KH
    Clin Cancer Res; 2017 Apr; 23(7):1748-1759. PubMed ID: 27702822
    [No Abstract]   [Full Text] [Related]  

  • 8. LAMC2 promotes cancer progression and gemcitabine resistance through modulation of EMT and ATP-binding cassette transporters in pancreatic ductal adenocarcinoma.
    Okada Y; Takahashi N; Takayama T; Goel A
    Carcinogenesis; 2021 Apr; 42(4):546-556. PubMed ID: 33624791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer.
    Venkatasubbarao K; Peterson L; Zhao S; Hill P; Cao L; Zhou Q; Nawrocki ST; Freeman JW
    Mol Cancer; 2013 Sep; 12(1):104. PubMed ID: 24025152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LIPH contributes to glycolytic phenotype in pancreatic ductal adenocarcinoma by activating LPA/LPAR axis and maintaining ALDOA stability.
    Han L; Jiang Y; Shi M; Gan L; Wu Z; Xue M; Zhu Y; Xiong C; Wang T; Lin X; Shen B; Jiang L; Chen H
    J Transl Med; 2023 Nov; 21(1):838. PubMed ID: 37990271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extracellular lumican augments cytotoxicity of chemotherapy in pancreatic ductal adenocarcinoma cells via autophagy inhibition.
    Li X; Roife D; Kang Y; Dai B; Pratt M; Fleming JB
    Oncogene; 2016 Sep; 35(37):4881-90. PubMed ID: 26876211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy of a novel, dual PI3K/mTOR inhibitor NVP-BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer.
    Awasthi N; Yen PL; Schwarz MA; Schwarz RE
    J Cell Biochem; 2012 Mar; 113(3):784-91. PubMed ID: 22020918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel DDIT3 activator dehydroevodiamine effectively inhibits tumor growth and tumor cell stemness in pancreatic cancer.
    Zhu SL; Qi M; Chen MT; Lin JP; Huang HF; Deng LJ; Zhou XW
    Phytomedicine; 2024 Jun; 128():155377. PubMed ID: 38503154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of the Nampt-mediated NAD salvage pathway and its therapeutic implications in pancreatic cancer.
    Ju HQ; Zhuang ZN; Li H; Tian T; Lu YX; Fan XQ; Zhou HJ; Mo HY; Sheng H; Chiao PJ; Xu RH
    Cancer Lett; 2016 Aug; 379(1):1-11. PubMed ID: 27233476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Purinergic GPCR-integrin interactions drive pancreatic cancer cell invasion.
    Tomas Bort E; Joseph MD; Wang Q; Carter EP; Roth NJ; Gibson J; Samadi A; Kocher HM; Simoncelli S; McCormick PJ; Grose RP
    Elife; 2023 Mar; 12():. PubMed ID: 36942939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Uridine triphosphate increases proliferation of human cancerous pancreatic duct epithelial cells by activating P2Y2 receptor.
    Choi JH; Ji YG; Lee DH
    Pancreas; 2013 May; 42(4):680-6. PubMed ID: 23462325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The interaction between UBR7 and PRMT5 drives PDAC resistance to gemcitabine by regulating glycolysis and immune microenvironment.
    Feng M; Jiao Q; Ren Y; Liu X; Gao Z; Li Z; Wang Y; Zhao M; Bi L
    Cell Death Dis; 2024 Oct; 15(10):758. PubMed ID: 39424627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FAM84B, amplified in pancreatic ductal adenocarcinoma, promotes tumorigenesis through the Wnt/β-catenin pathway.
    Zhang X; Xu J; Yan R; Zhang Y; Hu Z; Fu H; You Q; Cai Q; Yang D
    Aging (Albany NY); 2020 Apr; 12(8):6808-6822. PubMed ID: 32291380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low expression of the E3 ubiquitin ligase CBL confers chemoresistance in human pancreatic cancer and is targeted by epidermal growth factor receptor inhibition.
    Kadera BE; Toste PA; Wu N; Li L; Nguyen AH; Dawson DW; Donahue TR
    Clin Cancer Res; 2015 Jan; 21(1):157-65. PubMed ID: 25348515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRD4 promotes pancreatic ductal adenocarcinoma cell proliferation and enhances gemcitabine resistance.
    Wang YH; Sui YN; Yan K; Wang LS; Wang F; Zhou JH
    Oncol Rep; 2015 Apr; 33(4):1699-706. PubMed ID: 25647019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.